Due date extended for short term loan provided by Trans Nova

10/12/2012 10:06 AM EST

Affitech A/S
Company Announcement

Due date extended for short term loan provided by Trans Nova

Release no. 29/2012

Copenhagen and Oslo, 12th October 2012, 2012-10-12 16:06 CEST (GLOBE NEWSWIRE)
-- 
Affitech A/S, (NASDAQ OMX: AFFI), the antibody medicines company, announced
today that Trans Nova Investments Limited, the largest shareholder in Affitech
A/S with 76,78% ownership has agreed to extend the due date for the Euro 1.5
million short term loan provided in July 2012 and paid to Affitech in three
tranches in July, August and September 2012 . The due date has been extended
from 16th October, 2012 until 16th January, 2013. The other conditions for the
loan remain unchanged. 



About Affitech

Affitech A/S is a publicly traded (NASDAQ OMX Copenhagen) biotech company
head­quar­tered in Copenhagen, Denmark with R&D facilities in Oslo, Norway. The
company utilizes a range of proprietary antibody technologies for the discovery
of fully human antibodies for application in oncology, inflammation and other
disease areas. Affitech A/S antibody drugs targeting molecules on the cell
surface are developed through the Company’s proprietary CBAS™ (Cell Based
Antibody Selection). Affitech develops its two leading antibody drug candidates
AT001/r84 and AT008/CCR4 in collaboration with its Russian partner IBC
Generium.  Further information is available at www.affitech.com. 




         Contact:
         
         
         
         Stig Jarle Pettersen, CFO
         
         Tel +47 9096 0336
         
         
         
         Randi Krogsgaard, Director IR & Communications
         
         Tel # +45 2320 1001, e-mail: